State Street Corp Cidara Therapeutics, Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Cidara Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 271,537 shares of CDTX stock, worth $3.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

271,537

Previous 287,037 5.4%

Holding current value

$3.45 Million

Previous $226,000 10.18%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.64 - $0.92 $9,920 - $14,260	-15,500 Reduced 5.4%	271,537 $249,000
Q3 2023 Nov 14, 2023	BUY	$0.77 - $1.16 $25,410 - $38,280	33,000 Added 12.99%	287,037 $269,000
Q2 2023 Aug 14, 2023	SELL	$1.01 - $1.42 $21,412 - $30,104	-21,200 Reduced 7.7%	254,037 $287,000
Q1 2023 May 15, 2023	BUY	$0.75 - $1.98 $33,225 - $87,714	44,300 Added 19.18%	275,237 $349,000
Q3 2022 Nov 15, 2022	BUY	$0.45 - $0.81 $24,615 - $44,307	54,700 Added 31.04%	230,937 $145,000

Q1 2022 May 16, 2022	BUY	$0.67 - $1.39 $14,630 - $30,353	21,837 Added 14.14%	176,237 $147,000
Q4 2021 Feb 14, 2022	BUY	$1.18 - $2.18 $96,052 - $177,452	81,400 Added 111.51%	154,400 $196,000
Q2 2021 Aug 16, 2021	SELL	$1.87 - $2.7 $1.1 Million - $1.58 Million	-585,711 Reduced 88.92%	73,000 $147,000
Q1 2021 May 17, 2021	BUY	$2.06 - $3.01 $241,741 - $353,223	117,350 Added 21.68%	658,711 $1.75 Million
Q4 2020 Feb 16, 2021	BUY	$1.99 - $3.25 $148,676 - $242,814	74,712 Added 16.01%	541,361 $1.08 Million
Q3 2020 Nov 10, 2020	BUY	$2.85 - $4.1 $119,577 - $172,023	41,957 Added 9.88%	466,649 $1.33 Million
Q2 2020 Aug 14, 2020	BUY	$2.39 - $4.0 $1.02 Million - $1.7 Million	424,692 New	424,692 $1.57 Million

Others Institutions Holding CDTX

# of Institutions

Shares Held

22.1M

Call Options Held

2.7K

Put Options Held

100

View Full List

About Cidara Therapeutics, Inc.

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $889M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

More about CDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Cidara Therapeutics, Inc. Transaction History